BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 9478280)

  • 1. Issues in experimental design and endpoint analysis in the study of experimental cytotoxic agents in vivo in breast cancer and other models.
    Clarke R
    Breast Cancer Res Treat; 1997; 46(2-3):255-78. PubMed ID: 9478280
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel merosesquiterpene exerts a potent antitumor activity against breast cancer cells in vitro and in vivo.
    Carrasco E; Álvarez PJ; Melguizo C; Prados J; Álvarez-Manzaneda E; Chahboun R; Messouri I; Vázquez-Vázquez MI; Aránega A; Rodríguez-Serrano F
    Eur J Med Chem; 2014 May; 79():1-12. PubMed ID: 24704691
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antitumor activity of edotecarin in breast carcinoma models.
    Ciomei M; Croci V; Stellari F; Amboldi N; Giavarini R; Pesenti E
    Cancer Chemother Pharmacol; 2007 Jul; 60(2):229-35. PubMed ID: 17089166
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinically relevant metastatic breast cancer models to study chemosensitivity.
    Kim LS; Price JE
    Methods Mol Med; 2005; 111():285-95. PubMed ID: 15911986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Different response of murine and human mammary tumour models to a series of diastereoisomeric [1,2-bis(difluorophenyl) ethylenediamine]dichloroplatinum(II) complexes.
    Spruss T; Bernhardt G; Schickaneder E; Schönenberger H
    J Cancer Res Clin Oncol; 1991; 117(5):435-43. PubMed ID: 1890139
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis and structure-activity relationship of a focused library of β-phenylalanine derivatives as novel eEF2K inhibitors with apoptosis-inducing mechanisms in breast cancer.
    Guo Y; Zhao Y; Wang G; Chen Y; Jiang Y; Ouyang L; Liu B
    Eur J Med Chem; 2018 Jan; 143():402-418. PubMed ID: 29202403
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models.
    Hoeflich KP; O'Brien C; Boyd Z; Cavet G; Guerrero S; Jung K; Januario T; Savage H; Punnoose E; Truong T; Zhou W; Berry L; Murray L; Amler L; Belvin M; Friedman LS; Lackner MR
    Clin Cancer Res; 2009 Jul; 15(14):4649-64. PubMed ID: 19567590
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The indole alkaloid meleagrin, from the olive tree endophytic fungus Penicillium chrysogenum, as a novel lead for the control of c-Met-dependent breast cancer proliferation, migration and invasion.
    Mady MS; Mohyeldin MM; Ebrahim HY; Elsayed HE; Houssen WE; Haggag EG; Soliman RF; El Sayed KA
    Bioorg Med Chem; 2016 Jan; 24(2):113-22. PubMed ID: 26692349
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro and in vivo assessments of two novel hydrazide compounds against breast cancer as well as mammary tumor cells.
    Mousavi E; Tavakolfar S; Almasirad A; Kooshafar Z; Dehghani S; Afsharinasab A; Amanzadeh A; Shafiee S; Salimi M
    Cancer Chemother Pharmacol; 2017 Jun; 79(6):1195-1203. PubMed ID: 28451832
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Engineered thio-trastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancer.
    Junutula JR; Flagella KM; Graham RA; Parsons KL; Ha E; Raab H; Bhakta S; Nguyen T; Dugger DL; Li G; Mai E; Lewis Phillips GD; Hiraragi H; Fuji RN; Tibbitts J; Vandlen R; Spencer SD; Scheller RH; Polakis P; Sliwkowski MX
    Clin Cancer Res; 2010 Oct; 16(19):4769-78. PubMed ID: 20805300
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Melatonin Differentially Modulates NF-кB Expression in Breast and Liver Cancer Cells.
    Colombo J; Jardim-Perassi BV; Ferreira JPS; Braga CZ; Sonehara NM; Júnior RP; Moschetta MG; Girol AP; Zuccari DAPC
    Anticancer Agents Med Chem; 2018; 18(12):1688-1694. PubMed ID: 29384062
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo antitumor and antimetastatic effects of flavokawain B in 4T1 breast cancer cell-challenged mice.
    Abu N; Mohamed NE; Yeap SK; Lim KL; Akhtar MN; Zulfadli AJ; Kee BB; Abdullah MP; Omar AR; Alitheen NB
    Drug Des Devel Ther; 2015; 9():1401-17. PubMed ID: 25834398
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthetic antitumor vaccines containing MUC1 glycopeptides with two immunodominant domains-induction of a strong immune response against breast tumor tissues.
    Gaidzik N; Kaiser A; Kowalczyk D; Westerlind U; Gerlitzki B; Sinn HP; Schmitt E; Kunz H
    Angew Chem Int Ed Engl; 2011 Oct; 50(42):9977-81. PubMed ID: 21910197
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New Poly(3-hydroxybutyrate) Microparticles with Paclitaxel Sustained Release for Intraperitoneal Administration.
    Bonartsev AP; Zernov AL; Yakovlev SG; Zharkova II; Myshkina VL; Mahina TK; Bonartseva GA; Andronova NV; Smirnova GB; Borisova JA; Kalishjan MS; Shaitan KV; Treshalina HM
    Anticancer Agents Med Chem; 2017; 17(3):434-441. PubMed ID: 27141874
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic anti-tumor activity of Nimotuzumab in combination with Trastuzumab in HER2-positive breast cancer.
    Yang Y; Guo R; Tian X; Zhang Z; Zhang P; Li C; Feng Z
    Biochem Biophys Res Commun; 2017 Aug; 489(4):523-527. PubMed ID: 28579432
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treating breast cancer metastasis with cabazitaxel-loaded polymeric micelles.
    Zhong T; He B; Cao HQ; Tan T; Hu HY; Li YP; Zhang ZW
    Acta Pharmacol Sin; 2017 Jun; 38(6):924-930. PubMed ID: 28504249
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical orthotopic and intracardiac injection models of human breast cancer metastasis to bone and their use in drug discovery.
    Scepansky E; Goldstein R; Rosenblatt M
    Curr Protoc Pharmacol; 2011 Mar; Chapter 14():Unit 14.18. PubMed ID: 21935904
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-prostate cancer and anti-breast cancer activities of two peptides derived from alpha-fetoprotein.
    Caceres G; Dauphinee MJ; Eisele LE; MacColl R; Mizejewski GJ
    Anticancer Res; 2002; 22(5):2817-20. PubMed ID: 12530002
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preferential killing of breast tumor initiating cells by N,N-diethyl-2-[4-(phenylmethyl)phenoxy]ethanamine/tesmilifene.
    Deng T; Liu JC; Pritchard KI; Eisen A; Zacksenhaus E
    Clin Cancer Res; 2009 Jan; 15(1):119-30. PubMed ID: 19118039
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor and antimetastatic activities of chloroquine diphosphate in a murine model of breast cancer.
    Jiang PD; Zhao YL; Deng XQ; Mao YQ; Shi W; Tang QQ; Li ZG; Zheng YZ; Yang SY; Wei YQ
    Biomed Pharmacother; 2010 Nov; 64(9):609-14. PubMed ID: 20888174
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.